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Mammalian cells contain several proteolytic systems to carry out the degradative processes and complex regulatory mechan-
isms to prevent excessive protein breakdown. Among these systems, the Ca2+-activated proteolytic system involves the cysteine
proteases denoted calpains, and their inhibitor, calpastatin. Despite the rapid progress in molecular research on calpains and
calpastatin, the physiological role and regulatory mechanisms of these proteins remain obscure. Interest in the adrenergic effect
on Ca2+-dependent proteolysis has been stimulated by the finding that the administration of β2-agonists induces muscle
hypertrophy and prevents the loss of muscle mass in a variety of pathologic conditions in which calpains are activated. This
review summarizes evidence indicating that the sympathetic nervous system produces anabolic, protein-sparing effects on
skeletal muscle protein metabolism. Studies are reviewed, which indicate that epinephrine secreted by the adrenal medulla and
norepinephrine released from adrenergic terminals have inhibitory effects on Ca2+-dependent protein degradation, mainly in
oxidative muscles, by increasing calpastatin levels. Evidence is also presented that this antiproteolytic effect, which occurs
under both basal conditions and in stress situations, seems to be mediated by β2- and β3-adrenoceptors and cAMP-dependent
pathways. The understanding of the precise mechanisms by which catecholamines promote muscle anabolic effects may have
therapeutic value for the treatment of muscle-wasting conditions and may enhance muscle growth in farm species for economic
and nutritional purposes.
Key words: Epinephrine; Norepinephrine; Calpastatin; Calpain; Skeletal muscle
Presented at the IV Miguel R. Covian Symposium, Ribeirão Preto, SP, Brazil, May 23-25, 2008.
Research supported by FAPESP (#04/02674-0 and #06/0697-3) and CNPq (#305847/06-6 and #300440/05-7).
Received August 1, 2008. Accepted December 4, 2008
Brazilian Jour al of Medical and Biological R earch (2009) 42: 21-28
ISSN 0100-879X Review
Introduction
The sympathetic nervous system (SNS) utilizes two
major chemical signaling molecules: epinephrine (adrena-
line) that is secreted directly into the blood from the adrenal
medulla, and norepinephrine (noradrenaline) that is the
major neurotransmitter produced and released from pe-
ripheral sympathetic neurons, which are distributed widely
to different tissues and are associated with blood vessels.
Although it is well known that skeletal muscles receive a
cholinergic innervation from the motoneuron, evidence
indicates that adrenergic nerve terminals make close con-
tact with striated muscle fibers in mammals (1). However,
the physiological role of this innervation is far from being
well established.
It is well known that most of the metabolic actions of the
SNS in several tissues are exerted through a β-adreno-
ceptor-mediated increase in intracellular cyclic adenosine
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monophosphate (cAMP) and subsequent activation of
cAMP-dependent protein kinase (PKA). The intracellular
concentration of cAMP in cells is determined via the bal-
ance between cAMP production by adenylyl cyclase, and
cAMP degradation by phosphodiesterases (PDEs). Skel-
etal muscle contains numerous isoforms of PDE, including
PDE4, PDE7 and PDE8 (2). However, PDE4 appears to
contribute to the majority of cAMP degradation in this
tissue (3).
Historically, the physiological role of SNS is related to a
“fight or flight” response that prepares an organism to cope
with an emergency. Catecholamines decrease the uptake
of glucose in peripheral tissues, partly through an inhibition
of insulin secretion, stimulate glycogenolysis (4), increase
the diet-induced thermogenesis in brown adipose tissue
(5), stimulate the substrate oxidation in skeletal muscle (4),
and have a well-known stimulatory effect on white adipose
tissue lipolysis (6). They also have a marked effect on
protein metabolism in skeletal muscle. Numerous studies
have shown that β2-adrenergic agonists, such as clen-
buterol and cimaterol, induce hypertrophy of skeletal muscle
in livestock and humans (7). β-agonist-induced hypertro-
phy seems to be specific for striated muscle, since the
smooth muscle of the gut, liver, and kidney (8) do not
increase in size in response to these agents. It has also
been reported that treatment with β2-adrenergic agonists
reduces muscle wasting in different catabolic situations
including tumors, atrophy denervation, sepsis, muscular
dystrophy, hindlimb suspension, hyperthyroidism, burn-
ing, and diabetes (7,9,10). However, the biochemical mech-
anisms of these effects of β2-adrenergic agonists are not
completely understood.
Skeletal muscle protein mass depends on the balance
between synthesis and degradation. Even a small de-
crease in synthesis or a small acceleration of degradation,
if sustained, can result in a marked loss of mass in the
organism (11,12). The main intracellular proteolytic sys-
tems in the skeletal muscles are the lysosomal, the Ca2+-
dependent, and the ubiquitin-proteasome system. During
the last decade, we have been studying the mechanisms
through which the rates of these different proteolytic com-
ponents are regulated by hormonal, nutritional and neural
factors. This review will focus on recent studies of the
influence of the SNS on Ca2+-dependent proteolysis, as
well as on the mechanisms involved.
The role of the sympathetic nervous system
on muscle protein breakdown
Knowledge of the regulatory factors involved in the
control of the rates of protein degradation is important for
understanding the mechanisms by which hormones, neu-
rotransmitters, nutrition, growth promoting agents, and
environmental and genetic factors influence growth. In
order to investigate the physiological role of catechol-
amines in the control of protein breakdown in skeletal
muscles, we have been using the chemical sympathecto-
my experimental model in which rats are treated with
guanethidine for a few days (13). Guanethidine was cho-
sen because it has been shown to produce a selective
blockade of norepinephrine release from peripheral nerves
without affecting central adrenergic neurons (14). Gua-
nethidine treatment induces a drastic 90% reduction in
norepinephrine content of soleus muscles and a 40-80%
reduction in plasma levels of norepinephrine and epineph-
rine (13). After 1 and 2 days of guanethidine treatment,
there was a significant 20% increase in the rate of proteoly-
sis in incubated soleus muscles. Because this early rise in
the proteolytic rate occurred without a concomitant change
in the plasma levels of other hormones, it was interpreted
to be a direct consequence of the depletion of muscle
norepinephrine and/or of the reduction in plasma catechol-
amine concentration induced by guanethidine treatment.
Also, the acute increase in proteolysis after adrenergic
blockade suggested the existence of an inhibitory adrener-
gic tonus in oxidative skeletal muscles, which restrains
proteolysis (13). In agreement with this suggestion, we
have found that both epinephrine and norepinephrine,
added in vitro, reduce the rate of protein degradation in
normal rat soleus and extensor digitorum longus (EDL) by
approximately 15-20% (15). This view is consistent with
the finding that infusion of epinephrine in muscle microdi-
alysis experiments (16), in perfused rat hindquarters (17)
and in humans (18) induces a rapid and similar 20%
decrease in protein degradation.
Recently, we have investigated the role of the SNS in
the control of protein degradation in skeletal muscles from
rats with streptozotocin (STZ)-induced diabetes (19). It
has been shown that chemical sympathectomy by gua-
nethidine further increased the high rate of protein degra-
dation in soleus and EDL muscles during the early stages
of diabetes in rats (1 and 3 days after STZ). Although
guanethidine treatment induced a decrease in both plas-
ma epinephrine and muscle norepinephrine, the additional
increase in the proteolysis observed in muscles from sym-
pathectomized diabetic rats was probably a consequence
of the reduction in plasma epinephrine concentration (19).
It has been found that the acute reduction in rat plasma
catecholamines produced by surgical removal of the adre-
nal medulla, with no change in muscle norepinephrine
content, is accompanied by a transient increase in the rate
of skeletal muscle proteolysis (20). It has also been shown
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that the infusion of epinephrine in humans and animals
induces a rapid decrease in the activity (21) and gene
expression (22) of enzymes involved in muscle protein
breakdown. The fact that the effects of sympathectomy
were obtained in a condition of an acute catabolic state,
like diabetes, supports our previous hypothesis based on
experiments with chemical sympathectomy of normal rats,
that the SNS exerts an acute effect on skeletal muscle
protein metabolism, reducing proteolysis. This anabolic
effect of the SNS can be interpreted as a mechanism to
spare muscle protein in a situation of catabolism. In fact,
the drastic reduction of the catecholamine levels in dia-
betic-sympathectomized rats promoted an additional fall in
the body weight of these animals compared to the diabetic
group (19).
The finding that soleus was more sensitive than EDL to
the catabolic effect of sympathectomy in diabetic rats (19)
is consistent with our previous demonstration (15) that
soleus is more sensitive than EDL to the antiproteolytic
effect of epinephrine in vitro. This differential sensitivity
may be explained by differences in the density of β-adre-
noceptors and levels of PKA, which have been shown to be
higher in rat skeletal muscles rich in type I fibers (e.g.,
soleus) than in muscles containing mainly type II fibers
(e.g., EDL) (23,24). That the adrenergic inhibitory effects
on skeletal muscle proteolysis are mediated by β2-adreno-
ceptors had already been suggested by the in vivo hyper-
trophic effect of the β2-adrenergic agonists on skeletal
muscle of different species and by the suppression of the
clenbuterol-induced hypertrophy of rat gastrocnemius
muscles by oral administration of ICI 118,551, a selective
β2-adrenoceptor antagonist (25). Recent experiments from
our laboratory strongly support this hypothesis by demon-
strating directly in isolated skeletal muscle the mediation
by β2-adrenoceptors. Thus, the antiproteolytic effect of
epinephrine in soleus and EDL was completely suppressed
by propranolol and by ICI 118,551 (13). Clenbuterol in vitro
induced a dose-dependent inhibition of proteolysis that
was also prevented by ICI 118,551 in both muscles (20).
Numerous studies have shown that β3-adrenergic recep-
tors are also present in skeletal muscle (26,27). The pres-
ence in skeletal muscle of other types of β-receptors,
different from β1- and β2-adrenoceptors, was initially sur-
mised from the observation by Reeds et al. (28) that
propranolol blocked the clenbuterol-induced decrease in
body fat, but was not capable of reverting the increase in
rat skeletal muscle growth promoted by the β2-agonist.
This finding suggested the existence of β-adrenoceptors-
mediated responses clearly distinct from those mediated
by β1- and β2-adrenoceptors in muscle. The presence of
functional β3-adrenergic receptors in muscle has been
suggested by the metabolic effects of specific agonists in
vitro (29) and by the detection of the β3-adrenoceptor
protein and its mRNA in human (26) and rat (27) skeletal
muscle. The physiological role of muscle β3-adrenoceptor,
however, remains poorly understood. We have previously
shown that CL-316,243, a selective β3-adrenoceptor ago-
nist, exerts an inhibitory action on proteolysis in rat-iso-
lated soleus muscle. The inhibition of proteolysis induced
by the addition of CL-316,243 to the incubation medium of
soleus muscles from fed and fasted rats was completely
prevented by SR-59230A, a selective β3-antagonist, but
was not affected by selective β1- or β2-antagonists (30).
Furthermore, we have demonstrated that the inhibitory
effect of epinephrine on muscle protein degradation can
also be prevented by SR-59230A, suggesting that this
adrenergic effect may be mediated by β3-adrenoceptors
(30). It was interesting to note that, unlike soleus, the
overall rates of proteolysis observed in fast-twitch muscles,
such as EDL, from fed and fasted rats was not affected by
CL-316,243. Taken together, these results suggest that
epinephrine inhibits proteolysis by activating β2- and/or β3-
adrenoceptors in oxidative muscles such as soleus (20,30).
Further experiments are needed to determine the relative
sensitivity of the different muscle fiber types to the β3-
adrenergic agonist-mediated effects on proteolysis.
Mechanism of adrenergic inhibition of the
Ca2+-dependent proteolysis
The intracellular Ca2+-dependent proteolytic system
contains at least two ubiquitous enzymes: μ- (low Ca2+-
requiring form) and m-calpain (high Ca2+-requiring form).
Calpains do not degrade proteins to amino acids or even to
small peptides (31,32). In fact, calpains initiate myofibrillar
protein degradation by disassembling the outer layer of
proteins from the myofibril and releasing them as myofila-
ments. Although the proteasome, the proteolytic enzy-
matic complex of the ubiquitin-proteasome system, can
degrade the majority of intracellular proteins, it cannot
degrade myofibrillar proteins until they have been removed
from the myofibril by calpains. Therefore, it appears that
both calpains and the proteasome are responsible for
myofibrillar protein turnover. Calpains tend to be concen-
trated in the Z band of the sarcomere (33), the site where
disassembly begins (34). Since skeletal muscle cells con-
tain sufficient calpain to destroy all Z bands in these cells in
5-10 min, it is likely that in physiological conditions calpain
activity must be inactive most of the time (32). Calpain
activity is regulated by a variety of factors, including Ca2+,
phospholipids, a 30-kDa small calpain subunit, and
calpastatin, a widely distributed calpain-specific endoge-
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nous inhibitor (35). It is generally thought that the calpain-
calpastatin system plays a major role in muscle protein
degradation only when cytosolic Ca2+ homeostasis is al-
tered. Recent findings showing that calpastatin overex-
pression results in skeletal muscle hypertrophy (36) and
protects mice against atrophy (37) provide evidence that
calpastatin is also involved in the control of normal skeletal
muscle protein turnover. However, the physiological role
of neural and peripheral signals implicated in the control of
calpain and calpastatin activity in in vivo conditions is still
unknown.
In previous studies, we have demonstrated that the
increase in overall proteolysis observed after 2 days of
chemical (13) and surgical sympathectomy (20) is accom-
panied by a parallel increase in the activity of the Ca2+-
dependent system, suggesting that the restraining effect of
the adrenergic tonus on skeletal muscle proteolysis is
exerted, at least in part, by keeping the Ca2+-dependent
pathway inhibited. In agreement with these results, the
inhibitory in vitro effect of clenbuterol and CL-316,243 on
the rate of overall proteolysis in isolated skeletal muscle
from normal rats was shown to be associated with a
reduction in the activity of the Ca2+-dependent proteolysis,
an effect that was prevented by selective β2- and β3-
antagonists (20,30).
In view of the antiproteolytic effect of the SNS in skel-
etal muscles from normal rats, recent studies were under-
taken in our laboratory to examine the changes in the rate
of protein synthesis and activity of the different proteolytic
systems, which occur in oxidative muscles from rats sub-
mitted to 9 days of chronic intermittent hypoxia (CIH; 6%
O2 for 40 s at 9-min intervals; 8 h/day). Studies have shown
that rats submitted to CIH exhibited a higher level of basal
sympathetic activity, which, in turn, increased arterial pres-
sure (38,39). In addition to the lower rates of protein
synthesis observed in soleus muscles from rats exposed
to CIH, we also found a reduction in the rates of proteolysis
(Fabio TL, Gonçalves DA, Lira EC, Zanon NM, Bonagamba
LG, Zoccal DB, Kettelhut IC, Machado BH, Navegantes
LCC, unpublished data). The CIH-induced inhibition of
muscle proteolysis in rats was probably a direct conse-
quence of the muscle sympathoexcitation and can be
interpreted as an adaptive response of protein metabolism
that helps to prevent excessive loss of skeletal muscle
mass during prolonged hypoxic stress. Maintenance of
protein content is especially essential for red, oxidative
muscles, such as soleus, which serve the important func-
tion of sustaining most of the postural work of the animal.
The decrease in the overall proteolysis in soleus muscles
from rats exposed to CIH was accompanied by ~50%
decrease in the activity of muscle Ca2+-dependent pro-
teolytic pathway, with no changes in the activities of the
lysosomal and ubiquitin-proteasome systems. There is a
growing body of evidence that the activity and gene ex-
pression of calpastatin are increased after β2-adrenergic
agonists treatment (40-42), leading to the suggestion that
this is the mechanism of the inhibitory effect of catechol-
amines on the Ca2+-dependent proteolysis. This hypo-
thesis has been reinforced by the findings that CIH induces
an increase in calpastatin levels in soleus muscles from
rats. Similar results have been observed in soleus from
rats treated with clenbuterol for 3 days (Gonçalves DA,
Baviera AM, Lira EC, Zanon NM, Kettelhut IC, Navegantes
LC, unpublished data) and in muscles from humans after
acute exercise (43). Because catecholamines and β-ago-
nists activate PKA and may act via cAMP responsive
elements (CRE) in calpastatin promoter regions (44), it has
been proposed that calpastatin is a target for this kinase. In
agreement with this hypothesis, it has been shown that
calpastatin is phosphorylated by PKA (45) and its maximal
inhibitory activity against m-calpain is enhanced by phos-
phorylation in rat skeletal muscle in vitro (46). Moreover,
recent evidence indicates that the calpastatin gene pro-
moter is activated in rat muscle L6G8 cells transfected with
dibutyryl-cAMP or forskolin (47), suggesting that both the
calpastatin gene promoter and protein are targets for PKA
activity. The inhibition of Ca2+-dependent proteolysis by
nonhydrolyzable cAMP analogs and the activation of β2-
adrenergic receptor in vitro inhibit proteolysis in skeletal
muscle from normal rats (20) and chicks (48) are also
consistent with the results of the studies cited above.
These findings indicate that cAMP signaling may play
an important role in preventing proteolysis in physiological
conditions and raise the possibility of using drugs that
induce an increase in the intracellular concentrations of
cAMP, as the cAMP-PDE inhibitors, to prevent muscular
atrophy in several pathological situations. A nonselective
PDE inhibitor (pentoxifylline; PTX) or two different selec-
tive PDE4 inhibitors (cilomilast and rolipram) have been
administered to mice undergoing muscle atrophy, in order
to reduce skeletal muscle cAMP degradation, and thus
increase cAMP-mediated muscle hypertrophy (49,50). The
selective PDE4 inhibitor rolipram was shown to inhibit
protein degradation in muscles from normal rats (Lira EC,
Gonçalves DA, Baviera AM, Zanon NM, Kettelhut IC,
Navegantes LC, unpublished data) and to prevent the
muscle wasting and weakness associated with sciatic
nerve resection and limb casting (49). Treatment with PTX
induced a clear reduction in the high rates of muscle
protein degradation in tumor-bearing rats (51) and during
sepsis (52). In another study from our laboratory, Lira et al.
(53) perfused skeletal muscles from normal and septic rats
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with isobutylmethylxanthine, a nonselective PDE inhibitor,
and demonstrated that this compound increased muscle
cAMP levels and reduced muscle protein catabolism by
inhibiting proteolysis. More recently, Baviera et al. (54)
also demonstrated that the in vivo and in vitro treatment
with PTX increased muscle cAMP levels and induced a
decrease in the increased rate of total protein degradation
in EDL muscles from diabetic animals through a clear
reduction in the activity of the Ca2+-dependent and ubiqui-
tin-proteasome-dependent proteolytic systems, two deg-
radative processes well known to be activated in the acute
phase of experimental diabetes (55). The antiproteolytic
effect of PTX in vitro was inhibited by H89, a PKA inhibitor,
further supporting the idea that activation of the cAMP
cascade via a PKA-dependent pathway is one of the
regulatory mechanism(s) to prevent excessive skeletal
muscle protein breakdown. Although the PKA signaling
pathway is the most commonly studied β-adrenoceptor
effector in skeletal muscle (7), other studies have shown
that the production of cAMP by epinephrine in skeletal
muscle (56) may activate a novel protein termed EPAC
(exchange protein directly activated by cAMP). Therefore,
the possibility of PKA-independent signaling pathways in
regulating proteolysis cannot be ruled out.
Figure 1 illustrates the possible mechanisms by which
Ca2+-dependent proteolysis could be regulated by the
SNS in vivo. Catecholamines bind directly to β2- and β3-
adrenoceptors located in the sarcolemma, stimulate aden-
ylate cyclase activity, and consequently increase cAMP,
which stimulates PKA in skeletal muscles. This kinase
could increase calpastatin activity by direct phosphoryla-
tion and/or by increasing the levels of calpastatin mRNA by
Figure 1. Mechanisms in the inhibition of the Ca2+-dependent proteolysis in skeletal muscle by catecholamines and β-agonists. Gsα
= stimulatory alpha subunit of guanine nucleotide-binding regulatory protein; βγ = beta-gamma subunit of guanine nucleotide-binding
regulatory protein; ATP = adenosine triphosphate; cAMP = cyclic adenosine monophosphate; 5’AMP = 5’adenosine monophosphate;
PTX = pentoxifylline; IBMX = isobutylmethylxanthine; PDEs = phosphodiesterases; PKA = cAMP-dependent protein kinase; CREB =
cAMP responsive element binding protein.
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enhanced gene transcription through phosphorylation of
the cAMP responsive element binding protein (CREB) and
activation of CRE, which could keep the calpain activity
inhibited. Alternatively, calpain itself might be inhibited by
catecholamines through PKA-induced phosphorylation. In
fact, evidence in fibroblasts indicates that m-calpain can
be directly phosphorylated and inhibited by PKA (57).
More recently, it has been demonstrated that β2-adrener-
gic agonist treatment attenuates muscle atrophy induced
by hindlimb unweighting or atrophy denervation through
inhibitory effects on ubiquitin-proteasome system (58,59).
Thus, it could be speculated that proteasome and/or the
process of protein ubiquitination is also regulated by PKA
and/or EPAC.
Conclusion
In contrast to its catabolic effects on carbohydrate and
lipid metabolism, the SNS, through adrenal medulla-se-
creted catecholamines, and norepinephrine released by
adrenergic terminals exerts anabolic action on skeletal
muscle protein metabolism. In addition to the intrinsic
regulation of calpain by the Ca2+-requirement for the en-
zyme activity, and by levels, activity and isoform types of
calpastatin, catecholamines may contribute to maintain
muscle Ca2+-dependent proteolysis inhibited through a β2-
adrenoceptor/cAMP-mediated phosphorylation of compo-
nents of the calpain system, including CREB and
calpastatin. In oxidative muscles, such as soleus, at least
part of these effects can also be mediated by β3-adreno-
ceptors. This antiproteolytic effect seems to be important
for the preservation of muscle structure and function, mainly
in oxidative postural muscles in both basal conditions and
during stress situations. The anabolic actions of synthetic
catecholamines and/or cAMP-phosphodiesterase inhibi-
tors may also have therapeutic value in the treatment of
muscle-wasting conditions, such as diabetes and sepsis,
and may enhance muscle growth in farm animals for
economic and nutritional purposes. This emphasizes the
necessity of further studies to clarify the molecular mech-
anisms involved with the adrenergic control of protein
metabolism in skeletal muscle.
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